Prothena reported $271.37M in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 976.45M 19.97M Sep/2026
Agios Pharmaceuticals USD 128.55M 28.9M Sep/2026
Akebia Therapeutics USD 159.25M 3.71M Sep/2026
ALKERMES USD 631.31M 119.78M Sep/2026
Alnylam Pharmaceuticals USD 1.75B 46.02M Sep/2026
Amgen USD 13.19B 799M Sep/2026
Biogen USD 1.3B 18.9M Sep/2026
BioMarin Pharmaceutical USD 736.01M 138M Sep/2026
Exelixis USD 304.77M 23.33M Sep/2026
Immunic USD 131.96M 23.14M Sep/2026
Incyte USD 3.85B 127.8M Sep/2026
Ionis Pharmaceuticals USD 296.3M 53.76M Sep/2026
MacroGenics USD 49.03M 64.88M Sep/2026
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Neurocrine Biosciences USD 641.5M 309.1M Sep/2026
Prothena USD 271.37M 16.82M Sep/2026
Regeneron Pharmaceuticals USD 3.66B 1.2B Sep/2026
Ultragenyx Pharmaceutical USD 150M 25M Sep/2026
Vertex Pharmaceuticals USD 6.3B 1.55B Sep/2026